"Designing Growth Strategies is in our DNA"

U.S. Vaginal Atrophy Treatment Market Size, Share & Industry Analysis, By Therapy Type (Drug Therapies {Estrogen Based [Imvexxy, Premarin, and Others], Non-Estrogen Based [Intrarosa, Osphena, and Others]}, and Non-Drug Therapies {Light Therapy, Laser, and Others}), By Route of Administration (Oral, Parenteral, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Store & Pharmacies, and Online Channels), and Country Forecast, 2025-2032

Last Updated: April 07, 2025 | Format: PDF | Report ID: FBI109727

 

U.S. Vaginal Atrophy Treatment Market

Request Now
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Pipeline Analysis, By Key Players
    2. New Product Launches, By Key Players
    3. Prevalence of Vaginal Atrophy, U.S.
    4. Key Industry Developments, By Key Players
    5. Impact of COVID-19 on the Market
  5. U.S. Vaginal atrophy Treatment Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Therapy Type
      1. Drug Therapies
        1. Estrogen Based
          1. Imvexxy
          2. Premarin
          3. Others
        2. Non-Estrogen Based
          1. Intrarosa
          2. Osphena
          3. Others
      2. Non Drug Therapies
        1. Light Therapy
        2. Laser
        3. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
      3. Topical
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Store & Pharmacies
      3. Online Channels
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2024)
    2. Company Profiles
      1. TherapeuticsMD, Inc.
        1. Overview
        2. Products & services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      2. Millicent Pharma Ltd.
        1. Overview
        2. Products & services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. Duchesnay USA.
        1. Overview
        2. Products & services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. Novartis AG
        1. Overview
        2. Products & services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. Pfizer Inc.
        1. Overview
        2. Products & services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. Novo Nordisk Inc.
        1. Overview
        2. Products & services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. ASCEND Therapeutics
        1. Overview
        2. Products & services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      8. Joylux, Inc.
        1. Overview
        2. Products & services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      9. RB Health (US) LLC
        1. Overview
        2. Products & services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      10. BioFilm IP LLC
        1. Overview
        2. Products & services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
Read Less

Figure 1: U.S. Vaginal Atrophy Treatment Market Revenue Breakdown (USD billion, %) by Therapy Type, 2024 & 2032

Figure 2: U.S. Vaginal Atrophy Treatment Market Value Share (%), by Therapy Type, 2024 & 2032

Figure 3: U.S. Vaginal Atrophy Treatment Market Value Share (%), by Route of Administration, 2024 & 2032

Figure 4: U.S. Vaginal Atrophy Treatment Market Value Share (%), by Distribution Channel, 2024 & 2032

Figure 5: U.S. Vaginal Atrophy Treatment Market Share (%), By Company, 2024

Table 1: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, by Therapy Type, 2019–2032

Table 2: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, by Drug Therapies 2019–2032

Table 3: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, by Estrogen Based 2019–2032

Table 4: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, by Non-Estrogen Based 2019–2032

Table 5: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, by Non-Drug Therapies 2019–2032

Table 6: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 7: U.S. Vaginal Atrophy Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

U.S. Vaginal Atrophy Treatment Market Size, Share and Global Industry Trend Forecast till 2032
  • 2019-2032
  • 2024
  • 2019-2023
  • 88
Consulting Services
    How will you benefit from our consulting services ?